Drug intelligence / Profile preview

RPH-075

Development stage: Phase 1
Lead developer: R-Pharm
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

RPH-075 is a biosimilar of pembrolizumab developed by R-Pharm. Pembrolizumab is a humanized monoclonal antibody that targets the programmed cell death 1 receptor (PD-1), acting as an immune checkpoint inhibitor. By blocking PD-1, it enhances T lymphocyte activity against tumor cells. RPH-075 is being evaluated for equivalence in efficacy, safety, and immunogenicity compared to Keytruda (the reference pembrolizumab product) in patients with unresectable or metastatic skin melanoma and other malignant neoplasms. The drug is administered intravenously at a dose of 200 mg every three weeks[1][2][3][4][5].

Other names: pembrolizumab biosimilar (R-Pharm)

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on RPH-075.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RPH-075.

Explore the full profile